drugset / Trial / NCT02889848
Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This pilot study evaluates the safety and tolerability of a single injection of collagenase enzyme directly into a uterine fibroid in subjects already selected for hysterectomy or myomectomy. Fibroids contain excessive amounts of collagen and it is possible that digestion of collagen may be beneficial in reducing pain and bleeding associated with fibroids. Three subjects will be injected with saline only to evaluate the safety and effectiveness of the injection method. Additional subjects will then be injected with increasing doses of study drug.
Timeline
- Start
- 2016-10-27
- Primary completion
- 2018-10-05
- Completion
- 2018-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.05 mg/ml | Other |
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.1 mg/ml | Other |
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.2 mg/ml | Other |
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 1.16 mg | Other |